Botanical Review Team Develops “Post-CMC” Approach
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s Botanical Review Team has identified new ways to help assure the quality of complex natural mixtures. While not specified in the agency’s 2004 guidance on botanical drugs, the team is adding its “post-CMC” approach to conventional CMC analyses and “pre-CMC” agricultural oversight.
You may also be interested in...
Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design
Review documents show that Fulyzaq’s clear, if modest, treatment effect compared to placebo was buttressed by a series of exploratory subgroup analyses suggesting greater efficacy in sicker patients.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.